Trial intelligence / Profile preview

Phase 1 avapritinib study in advanced GIST and other relapsed or refractory solid tumors

NL-OMON50464Phase 1Active, not recruiting

Sponsor
Blueprint Medicines
Start
Jan 2016
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 1, open-label trial of avapritinib in gastrointestinal stromal tumor (GIST) and Nonhematologic neoplasms (3 arms), sponsored by Blueprint Medicines. Primary endpoints: Maximum tolerated dose and recommended phase 2 dose, Safety and tolerability and 1 more. Started Jan 2016; status: active, not recruiting.

02

Drugs

avapritinib
03

Conditions

gastrointestinal stromal tumor (GIST)Nonhematologic neoplasms

Beyond the preview

Go deeper on NL-OMON50464.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NL-OMON50464.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call